Hims & Hers Adds Peptides+ to Diversify Beyond Weight Loss, but Core Margin and Legal Risks Remain
Read source articleWhat happened
Hims & Hers launched Peptides+, a new specialty offering personalized peptide-based treatments including Sermorelin, NAD+, Glutathione, Vitamin B12, and L-Carnitine after provider consultation. The move expands the platform beyond its recent weight-loss focus and could attract customers interested in anti-aging and wellness, potentially lifting subscriber growth. However, many peptide therapies are not FDA-approved for these uses, increasing regulatory risk at a time when the company already faces FTC and state litigation over privacy and billing practices. The launch does not address the company's core problem: gross margin compression from branded GLP-1 products, which fell to 64% in Q2 2026 from 76% a year earlier. The new specialty is unlikely to materially improve near-term profitability and may add complexity and legal exposure, leaving the Wait rating intact.
Implication
For investors, Peptides+ offers incremental product breadth that could attract new subscribers and increase customer lifetime value if demand for peptide-based wellness grows. However, the financial impact is likely to be small relative to the weight-loss business, which drove Q2 2026 revenue to $753M but compressed gross margin to 64%. The use of peptides like BPC-157 (if included) raises regulatory concerns because such compounds are not approved for human consumption, potentially inviting FDA scrutiny and adding to legal risks. Until Hims demonstrates that gross margin can recover above 66% and that the FTC case does not impair customer acquisition, the stock should be treated as a high-risk transition story. We see no reason to change the Wait rating; attractive entry remains near $24, and any upside requires clear evidence of margin improvement and legal containment.
Thesis delta
The launch of Peptides+ is a minor positive for diversification, but it does not alter the core thesis that Hims must prove branded weight-loss economics can recover margins. If anything, the addition of potentially unapproved peptide therapies adds regulatory uncertainty to an already fraught legal situation. The Wait rating is reaffirmed.
Confidence
Medium